Avec les compliments des éditions S. Karger, Bâle Mit den besten Empfehlungen des Verlags S. Karger, Basel ration at baseline. Methods: ADEPT was a placebo-controlled, phase III study of adalimumab in patients with active PsA ( 6 3 swollen and 6 3 tender joints) who had failed NSAID therapy. Patients were stratified by methotrexate use (yes/no) and degree of psoriasis ( ! 3% and 6 3% involvement of body surface area) and randomized to receive adalimumab 40 mg every other week or placebo for 24 weeks. Upon completion of ADEPT, adalimumab and placebo patients were eligible to receive adalimumab 40 mg every other week in the OLE trial. The present post hoc analysis categorized patients according to PsA duration as follows: ! 2, 2 to ! 5, 5 to ! 10, and 6 10 years at baseline. Analyses were conducted on the intention-to-treat population, using nonresponder imputation for the American College of Rheumatology (ACR) scores and last observation carried forward for other clinical scores. Results: A total of 313 patients (151 adalimumab, 162 placebo) enrolled in ADEPT and 285 entered the OLE trial. Baseline data were similar between randomization groups. ACR20/ 50/70 responses at week 24 were 57/39/23 for adalimumab versus 15/6/1 for placebo, and at week 48 they were 61/46/31 for patients from the adalimumab randomization arm. Among patients in the adalimumab treatment arm, baseline duration of PsA was ! 2 years for 26 patients, 2-5 years for 29, 5-10 years for 35 and 6 10 years for 61 (table 1) . Within each adalimumab disease duration group, the week 24 ACR20/50/70 response rates and mean changes in Health Assessment Questionnaire (HAQ) and Disease Activity Score (DAS28) scores (table 1) , as well as the mean changes in tender and swollen joint counts (TJC, SJC) and C-reactive protein (CRP) concentrations were better than in the corresponding groups of placebo patients (data not shown). No significant differences were observed in comparisons of these week 24 measures across the four disease duration groups. Among patients treated with adalimumab for 48 weeks, ACR responses were maintained in each disease duration group, and the mean changes in TJC, SJC, HAQ, CRP and DAS28 at week 48 were all equal to or greater than the mean changes observed at 24 weeks. Adalimumab was generally safe and well tolerated during the blinded phase of ADEPT and the first 24 weeks of the OLE trial ( 
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Seven Years Experience with Raptiva: CLEARESTTM, a LongTerm European Cohort Study to Evaluate the Safety of Raptiva in Psoriasis Patients
Francois Curtin, Florence Casset-Semanaz Serono International SA, Geneva, Switzerland Introduction: Raptiva is a recombinant humanized IgG monoclonal antibody which binds to leukocyte CD11a. This prevents the activation and trafficking of lymphocytes to the skin. Raptiva is indicated for the treatment of moderate to severe psoriasis. The efficacy and safety of Raptiva has been demonstrated in several studies. Methods: The objective of this study is to assess the safety of Raptiva during longterm psoriasis treatment and to quantify the incidence of specific serious conditions occurring during treatment with Raptiva in European clinical practice. Results: The study is an observational cohort study of psoriasis patients starting or already under treatment with Raptiva. The cohort will be followed for up to 7 years, and 7,000 European patients will be included at a rate of 1,000 patients per year. The major endpoints will be serious adverse events occurring during treatment. The incidence of these events will be quantified and compared to the incidence of similar events observed in psoriasis patients not treated with Raptiva included in the General Practice Research Database, a large British pharmacoepidemiological database. Discussion: This study will provide invaluable information on the safety profile of Raptiva and on the health conditions of patients with psoriasis. Introduction: Efalizumab is a humanized monoclonal antibody binding to CD11a, a co-stimulatory receptor expressed on T cells. It inhibits several cellular functions, such as T-cell activation and trafficking, and is indicated for the treatment of patients with chronic plaque psoriasis. Psoriasis is a chronic immune-mediated disease associated with patient disability and high impact on quality of life. A long-term safe control of clinical signs and symptoms together with an improvement of the patient's quality of life are the goals of treatment for psoriasis. Thus, long-term safety is a key priority in managing this disease. We present here a pooled 60-week safety and tolerability analysis from 2 long-term clinical trials. Methods: Data from 2 open-label studies (No. 2243: 3-year study, and 2601: 60-week study) were pooled at a cut-off of 60 weeks of data, and the incidence of adverse events (AEs) was analysed with descriptive statistical methods. Studies 2243 and 2601 enrolled 339 and 668 patients, respectively. Efalizumab was administered subcutaneously once weekly. For the purpose of the analysis, the treatment phases were divided into consecutive 12-week segments where a total of 1,007, 911, 814, 745 and 537 patients were evaluated throughout the respective 5 segments of these 60-week pooled data. Results: The rate of withdrawal during each 3-month treatment segment was low and stable (range 6.8-10.7%). As observed in previous efalizumab clinical trials, the most frequently observed AEs were of an acute type, predefined as headache, fever, chills, nausea and myalgia occurring within 48 h following efalizumab administration. These acute AEs were mostly seen during the first 2 weeks of therapy. No new common AEs appeared nor was there any increase in the incidence of AEs with long-term efalizumab therapy. Serious AEs occurred in 2-3% of patients during each 12-week period. No increased incidences of infection or malignancies were observed. Discussion: These individual studies and pooled results further confirm that the good safety and tolerability profile of efalizumab is maintained for up to 3 years of continuous weekly therapy. These findings must be confirmed by long-term observation in a larger cohort of patients. 
